8 Nov 2011
ERJ staff report (DS)
Lionville, Pennsylvania - West Pharmaceutical Services, Inc. has announced its financial results for the third quarter of 2011. Third-quarter 2011 net sales of $293.6 million were 8.2 percent higher than the same period last year, or 3.5 percent higher excluding the favorable effects of currency translation.
The Company updated full-year estimated 2011 financial guidance for sales, to between $1.18 and $1.20 billion, and for Adjusted Diluted EPS, to between $2.28 and $2.35 per share.
The Company updated its long-term outlook for sales and profitability, indicating that its long-term planning objectives include revenues in the range of $1.7 billion to $1.9 billion and an operating profit margin percentage in the high teens in 2016, the final year in its long-term planning cycle.
This is an external link and should open in a new window. If the window does not appear, please check your pop-up blocking software. ERJ is not responsible for the content of external sites.
Press release from West Pharmaceutical
Subscribe for unlimited access. A subscription to European Rubber Journal includes:
Already a subscriber? Log in here
